50 Most Trustworthy Companies of the Year 2021
The Silicon Review
In recent years, the power of regenerative medicine has been proven to be highly successful in treating chronic conditions. One of the forefront players in the breakthrough regenerative medicine space is Illinois-based Russell Health, which is providing innovative, life-changing, and sustainable products and therapies to patients and healthcare providers around the world.
The story of Russell Health began when Ryan Salvino, CEO and Co-Owner, was an MBA candidate serving as a sales representative for a regenerative medicine company. He was able to experience regenerative medicine’s revitalizing effects first-hand working in the industry. Ryan collaborated with his childhood friend Jonathan Benstent, VP and Co-Owner of Russell Health, with an aim to provide life-changing regenerative therapy products to physicians and patients globally. Jonathan is a graduate of Management Information Systems, and witnessed the potential of regenerative medicine during his tenure selling orthopedics medical devices and servicing Level-1 Trauma Centers while assisting in surgical cases as a device consultant. Together in 2017, they established Russell Health—a unique distribution model that allows hundreds of thousands of physicians to utilize these regenerative therapy products for multiple severe tissue disorders when all other treatments have failed.
In a brief interview, Ryan Salvino explained the benefits of the company’s Human Tissue Therapy, and more. Read on for the excerpts from the interview.
Q. Where do you stand as a company in the current market landscape? And what are you doing to stay ahead of the curve?
We work with the top scientists in the regenerative medicine field and are very excited about the launch of our new placental-derived tissue allograft products that are designated by the FDA as 361 HCT/P products. These allografts are regulated under 361 of the Public Health Service Act and 21 CFR Part 1271. Furthermore, these tissue allografts are classified by the Food and Drug Administration (FDA) as Human Cell, Tissue and Cellular and Tissue-Based Products (HCT/P) that are registered solely under the Public Health Service (PHS) Act. We look forward to introducing these products to a larger variety of physicians in different specialties, such as orthopedics, pain management, wound care, podiatry, plastic surgery and reconstructive surgery. As always, we will continue to work on breakthrough products in the market to stay abreast on the new technologies and innovations in the field.
Q. Human Tissue Therapy is based on a new technology. How do you ensure the safety and efficacy of your products?
Human Tissue Therapy products are prepared from a donor determined to be suitable based on the results of screening and testing. The tests for transmissible infectious diseases produced negative results. The names and addresses of the testing laboratories, the listing and interpretation of all required infectious disease tests, and a listing of the documents reviewed as part of the relevant medical records are on file and available upon request. Due to limitations in testing technology, testing and donor screening cannot totally eliminate the risk that human tissue will transmit disease. The donor has been evaluated and has been determined to be suitable for transplantation based on the donor suitability criteria current at the time of tissue recovery in accordance with United States Food and Drug Administration (FDA) regulations, local and state regulations, and tissue bank protocols. All communicable disease testing was performed on this allograft by a laboratory registered with FDA to perform donor testing and certified to perform testing on human specimens under the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. 263a and 42 CFR Part 493); or has met equivalent requirements as determined by the Centers for Medicare and Medicaid Services in accordance with those provisions. Human Tissue Therapy products are tissue allografts that are minimally manipulated, FDA-compliant and sourced from placental tissue from healthy, full-term donors intended for homologous use. The human tissue allograft products used in these treatments are human tissue products for transplantation. These allografts are processed and distributed in accordance with FDA requirements for Human Cellular and Tissue-based Products (HCT/P) (21 CFR Part 1271), State regulations, and the Standards of the American Association of Tissue Banks (AATB). These allografts are regulated under 361 of the Public Health Service Act and 21 CFR Part 1271. Furthermore, these tissue allografts are classified by the Food and Drug Administration (FDA) as Human Cell, Tissue and Cellular and Tissue-Based Products (HCT/P) that are registered solely under the Public Health Service (PHS) Act. FDA recognizes that human tissue was designed, or evolved, to perform certain functions in the human body with exquisite safety and effectiveness. As an HCT/P regulated solely under the PHS Act, Russell Health’s Human Tissue Therapy products are exempt from FDA pre-market review, clearance, and approval from the FDA.
Q. How do your Human Tissue Therapy products help the body boost its ability to heal itself?
Human Tissue Therapy products utilize responsibly sourced acellular tissue allografts, which are helping people of all ages to recover from injuries and get their life back. By using a combination of growth factors and other endogenously synthesized molecules, Human Tissue Therapy products help to assist the body with repair, reconstruction and supplementation of the recipient’s tissues. Acellular tissue allografts take advantage of the body’s ability to repair itself. All of our Human Tissue Therapy products utilize acellular, minimally manipulated tissue allografts and are comprised of tissue allograft components intended for homologous use to supplement tissue. As previously discussed, tissue allografts are classified by the Food and Drug Administration (FDA) as Human Cell, Tissue and Cellular and Tissue-Based Products (HCT/P) and are regulated solely under section 361 of the Public Health Service (PHS) Act. Additionally, tissue allografts contain hyaluronic acid, which helps lubricate joints and tendons.
Q. How does Russell Health help its client find the right therapy that is suitable for them?
We provide a large variety of products that are used for all different types of specialties and are used at the discretion of the physician or medical provider. Based on the type of disorders or body area the physician is trying to treat, we can provide the physicians with guidance on which tissue products could be best suited for their needs.
Q. What key milestones has Russell Health accomplished?
Russell Health has been awarded the Most Promising BioTech Start-up in 2020, 50 Leading Companies of the Year 2021, Best Specialty Regenerative Therapy Products Distributor and 20 Leading Companies of the Year 2021. We work with the top scientists in the regenerative medicine field and are very excited about the launch of our new placental-derived tissue allograft products that are designated by the FDA as 361 HCT/P products.
Q. Is it true that striving for both ‘ethics’ and ‘success’ in a business is a tough feat?
Ethical business operations are very important to succeed, while unethical behavior can be immensely damaging to a business. We at Russell Health are always ensuring that each and every one of our employees strives for both high-quality service and ethical behavior that includes honesty, fairness, integrity and understanding. Our Russell Health executive team promotes an ethical culture by continuing to build a team of managers who are genuinely dedicated to upholding high ethical standards, as well as by establishing our specific code of ethics for employees to follow. We will continue to look for individuals who demonstrate principled behavior because this proves that the individual has a strong moral code and a consistent set of values. Ethics can be rooted in the pursuit of making the world better, which is why we always put our customers and their patients first.
Q. What are you doing to ensure you continue to grow and develop as a leader?
Russell Health distinguishes itself from the competitors with an innovative and superior-quality bouquet of services. The team at Russell Health has been committed to ensuring the best client experience since the beginning. Consequently, the company experienced organic growth within just a few months of its inception and it has been escalading quickly since that time. All of these factors have contributed to making Russell Health the national distributor of safe and effective regenerative therapy products.
Due to the positive experience with Russell Health, several clients have pointed other patients and physicians in our direction. Word-of-mouth has been one of the main pillars for the growth of Russell Health. The company has achieved profound clinical outcomes in multiple therapeutic areas, including cosmetics, wound care, ocular, pain management, and orthopedics. Today, the platform has integrated dedicated products for specific applications sourced from the same acellular tissue allografts used in Human Tissue Therapy.
Ryan Salvino, CEO: Ryan was accepted into Chicago Medical School—Rosalind Franklin University, yet his passion for and natural strength in business leadership altered his career plans. Ryan redirected his goals and earned his MBA from DePaul University in Chicago. Before co-founding Russell Health, he was the Co-Founder and CEO of Zaptones, LLC, a social network that brings music and photo sharing together in one place. He is also the founder of Everheal, an innovative medical device company.